CompletedPhase 3ACTRN12611000491965

MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: Neuroprotection Trial

Does antenatal magnesium sulphate given to women at risk of imminent preterm birth (defined as planned or definitely expected in the next 24 hours) between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children at 2 years corrected age? - a randomised controlled trial

Sponsor

University of Adelaide

Enrollment

1,676 participants

Start Date

Jan 31, 2012

Study Type

Interventional

Conditions

Complications of preterm infant Cerebral Palsy Neuroprotection

Summary

Antenatal magnesium sulphate is recommended prior to preterm birth at less than 30 weeks’ gestation for neuroprotection of the fetus. Whether there are benefits at later gestations is uncertain. The primary aim of this randomised placebo controlled trial is to assess whether giving magnesium sulphate compared with placebo to women immediately prior to preterm birth between 30 and 34 weeks' gestation reduces the risks of death or cerebral palsy in their children at 2 years' corrected age. years' corrected age.

Eligibility

Sex: FemalesMin Age: 16 YearssMax Age: 50 Yearss

Plain Language Summary

Simplified for easier understanding

The MAGENTA trial tests whether giving magnesium sulphate to women at risk of preterm birth between 30-34 weeks of pregnancy can protect the baby's brain development. Magnesium sulphate has shown neuroprotective benefits at earlier gestational ages, and this trial extends the research to later preterm births. Eligible women aged 16-50 must have a singleton or twin pregnancy with birth expected within 24 hours.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Magnesium Sulphate (8% solution)- 50 ml infusion equivalent to 4g magnesium sulphate heptahydrate (16 mmol magnesium ions) administered through a dedicated intravenous line over 30 minutes. This is administered to women at risk of preterm birth between 30 and 34 weeks' gestation when birth is imminent (defined as planned or definitely expected in the next 24 hours).